A carregar...
Publicação
Lesão renal aguda e COVID-19
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.56 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
A doença por coronavírus 2019 (COVID-19) é a doença provocada pelo novo coronavírus 2, que foi identificado pela primeira vez em dezembro de 2019, em Wuhan (China), no contexto de um conjunto de casos de pneumonia atípica na região. Esta é caracterizada pelo desenvolvimento da síndrome respiratória aguda grave por coronavírus 2 (SARS-CoV-2), responsável por milhares de hospitalizações por todo o mundo. O grande aumento do número de casos a nível mundial levou a que a Organização Mundial de Saúde declarasse a situação de pandemia em março de 2020. O primeiro caso em Portugal foi identificado no dia 2 de março de 2020. As manifestações clínicas variam desde casos assintomáticos, a casos ligeiros, com sintomas inespecíficos como febre, tosse, dispneia, cefaleias e sintomas gastrointestinais. No entanto, nos casos mais graves, a doença pode levar a quadros clínicos de pneumonia grave e conduzir ao desenvolvimento de síndrome de dificuldade respiratória aguda (acute respiratory distress syndrome – ARDS), envolvimento multiorgânico e morte. O desenvolvimento de lesão renal aguda (LRA) associada à COVID-19 tem sido demonstrado em todo o mundo, e a sua incidência varia entre 0.5 e 57%. Nos doentes críticos internados em Unidades de Cuidados Intensivos (UCI), a lesão renal aguda afeta entre 20-40% dos doentes com COVID-19, associando-se a piores resultados e agravando a doença subjacente. O objetivo deste trabalho consistiu em avaliar a incidência de LRA, e o seu prognóstico nos doentes internados por COVID-19 no Centro Hospitalar Universitário Lisboa Norte.
Coronavirus disease 2019 (COVID-19) is the disease caused by the new coronavirus 2, first identified in December of 2019, in Wuhan (China), responsible for causing a number of cases of atypical pneumonia. This disease is associated with severe acute respiratory distress syndrome (ARDS), and has caused thousands of hospitalizations. It rapidly spread all over the globe, leading to the declaration of a pandemic in march of 2020 by the World Health Organization (WHO). In Portugal, the first case was identified on march 2nd, 2020. The clinical manifestations can vary from asymptomatic to mild cases, presenting with nonspecific symptoms like fever, cough, dyspnea, headaches and gastrointestinal symptoms. In more severe cases, this disease can be responsible for severe cases of pneumonia, leading to acute respiratory distress syndrome (ARDS), multiorganic involvement and death. The development of acute kidney injury (AKI) in COVID-19 patients has been identified all over the world, and its incidence varies from 0.5 to 57%. In the more critically ill patients, AKI affects 20 to 40% of COVID-19 patients admitted to intensive care units (ICU) and it is associated with worse outcomes. The main goal of this study was to analyze the incidence and prognosis of AKI in COVID-19 patients admitted to Centro Hospitalar Universitário Lisboa Norte.
Coronavirus disease 2019 (COVID-19) is the disease caused by the new coronavirus 2, first identified in December of 2019, in Wuhan (China), responsible for causing a number of cases of atypical pneumonia. This disease is associated with severe acute respiratory distress syndrome (ARDS), and has caused thousands of hospitalizations. It rapidly spread all over the globe, leading to the declaration of a pandemic in march of 2020 by the World Health Organization (WHO). In Portugal, the first case was identified on march 2nd, 2020. The clinical manifestations can vary from asymptomatic to mild cases, presenting with nonspecific symptoms like fever, cough, dyspnea, headaches and gastrointestinal symptoms. In more severe cases, this disease can be responsible for severe cases of pneumonia, leading to acute respiratory distress syndrome (ARDS), multiorganic involvement and death. The development of acute kidney injury (AKI) in COVID-19 patients has been identified all over the world, and its incidence varies from 0.5 to 57%. In the more critically ill patients, AKI affects 20 to 40% of COVID-19 patients admitted to intensive care units (ICU) and it is associated with worse outcomes. The main goal of this study was to analyze the incidence and prognosis of AKI in COVID-19 patients admitted to Centro Hospitalar Universitário Lisboa Norte.
Descrição
Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2021
Palavras-chave
SARS-CoV-2 COVID-19 Coronavírus Lesão renal aguda Doença renal Nefrologia